Cumberland Pharma shares slide on regulatory delay; Roche buying BioImagene for $100M;

 @FierceBiotech: U.S. biotech faces fierce international competition. Report | Follow @FierceBiotech

> Shares of Cumberland Pharmaceuticals took a hit after the FDA informed the biotech that it was extending its review of an experimental therapy for acute liver failure--Acetadote--by three months. CPIX stock slid 10 percent on the news that a final decision would have to wait until December. Story

> Solidifying its commitment to diagnostics, Roche announced a deal to buy BioImagene for $100 million. The pharma giant has staked out a big role for advanced diagnostics in creating a new generation of personalized therapies. Report

> Torbjorn Bjerke has been appointed as new CEO for Karolinska Development. He is currently CEO for Orexo, a position he has held since 2007. Torbjorn Bjerke succeeds Conny Bogentoft who will assume the position as Chief Scientific Officer for Karolinska Development. Karolinska release

> Eli Lilly says that it is shuttering a manufacturing facility for Erbitux at the ImClone Systems campus. Story

And Finally... Institute of Food Research scientists are developing new fats that are digested more slowly, spurring a sense of satiety that can promote weight loss. IFR release